FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Using a virtual clinical trial model to maximize patient access and enrollment, this study is NGS to 10,000 men with metastatic PC (Mpc). Patients with histologically-documented mPC and surplus formalin-fixed paraffin-embedded tumor tissue are eligible for enrollment. Leftover archival tissue is submitted for NGS to Strata Oncology, a clinical laboratory improvement amendments (CLIA)-certified lab. The Strata NGS assay sequences DNA and RNA, and simultaneously detects a range of actionable genomic alterations including gene mutations, small insertions and deletions, copy number changes, and gene fusions in 87 cancer-related genes. Microsatellite instability status is determined via the number of length variant alleles observed in NGS sequencing data at several microsatellite loci. Test reports that will be presented to the clinician, will include all positive and negative variants detected, and information regarding potential matching therapeutic protocols. Clinical trial information: NCT03061305
Presented by: Won Kim, MD University of California, San Francisco, USA
Co Authors: Kat Kwiatkowski, Justin Brown, Dan R Rhodes, Scott A Tomlins, Felix Y Feng, Eric Jay Small; University of California San Francisco, San Francisco, CA; Strata Oncology, Ann Arbor, MI
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA